Catalyst Biosciences Announces Oral and Poster Presentations at the International Conference on Complement Therapeutics
September 09 2021 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented data at
the International Conference on Complement Therapeutics (ICCT),
being held September 8-13, 2021.
The oral presentation, “Complement Factor I (CFI) as a Protease
Medicine: Engineered New Therapeutics for Complement-Mediated
Disorders,” was presented by Natacha Le Moan, Ph.D., executive
director, translational research, Catalyst Biosciences. This study
described the use of Catalyst’s proprietary ProTUNETM platform to
engineer a diverse library of enhanced CFI proteases that degrade
C3b and/or C4b. Administration of the degraders resulted in
improved cleavage of C4b and C3b as well as significant protection
against an inflammatory cytokine response in a preclinical rodent
model of sepsis.
The poster, “Enhanced Complement Factor I (CFI) properties of CB
4332 for replacement therapy in CFI deficiency,” by Eduard Gorina,
M.D., vice president, clinical development, Catalyst Biosciences,
demonstrated that CB 4332 showed improved pharmacokinetic
properties in monkeys when compared with plasma-derived human CFI
and comparable efficacy to plasma CFI. The data support a
convenient weekly SQ dosing if confirmed in the first-in-human
trials expected to commence enrollment in 2022. CB 4332 is
Catalyst’s wholly owned, first-in-class, enhanced CFI, intended for
prophylactic subcutaneous (SQ) administration in individuals with
CFI deficiency.
"CFI deficiencies are genetic abnormalities that can increase
susceptibility to infections caused by encapsulated bacteria or
incidences of autoimmune and immune-complex diseases. The positive
preclinical data presented at ICCT indicate that CB 4332 has the
potential to be an effective replacement therapy in CFI-deficient
patients by addressing the root cause of the deficiency,” said
Nassim Usman, Ph.D., president and chief executive officer of
Catalyst.
Dr. Usman continued, “Our complement portfolio, which we started
building with CB 2782-PEG, a novel C3 degrader targeting dry AMD,
now consists of two additional platforms - CFI-based proteins that
can be used in a wide variety of complement diseases and
immunomodulatory molecules, studying inflammation. We’re looking
forward to providing additional updates from our complement
programs.”
Catalyst recently launched the ConFIrm study with the screening
of the first patient. The ConFIrm screening study will measure CFI
levels and activity in patients who have diseases related to a CFI
deficiency and who may potentially benefit from CB 4332 treatment.
Those subjects with a confirmed CFI deficiency may subsequently
enroll in the ConFIdence natural history study. Catalyst
anticipates the submission of an Investigational New Drug (IND)
application and initiation of a global clinical trial for CB 4332
in CFI deficiency in 2022.
A copy of the presentation materials can be accessed on the
Scientific Publications section of the Catalyst website.
About Catalyst Biosciences, the Protease Medicines
companyCatalyst is a research and clinical development
biopharmaceutical company focused on addressing unmet medical needs
in rare disorders of the complement and coagulation systems. Our
protease engineering platform has generated two late-stage clinical
programs, including MarzAA, a subcutaneously (SQ) administered
next-generation engineered coagulation Factor VIIa (FVIIa) for the
treatment of episodic bleeding in subjects with rare bleeding
disorders. Our complement pipeline includes a preclinical
C3-degrader program licensed to Biogen for dry age-related macular
degeneration, an improved complement factor I protease for SQ
replacement therapy in patients with CFI deficiency and proteases
from our ProTUNE™ C3b-C4b degrader and ImmunoTUNE™ C3a-C5a degrader
platforms designed to target specific disorders of the complement
or inflammatory pathways as well as other complement programs in
development.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. Forward-looking statements include,
without limitation, statements about the product candidates
of Catalyst Biosciences, Inc. (the “Company”) and the
benefits of its protease engineering platform; plans to complete
the ConFIrm and ConFIdence studies and the expectation that the
studies will inform opportunities to develop CB 4332; plans to
submit an IND; the potential markets for and advantages of the
Company's complement product candidates, including CB 2782-PEG, CB
4332 and complement degraders; plans for the Company's
collaboration with Biogen; and plans to start a global clinical
trial of CB 4332 in 2022.
Actual results or events could differ materially from the plans,
intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially, including, but not
limited to, the risk that trials and studies may be delayed as a
result of COVID-19, competitive products and other factors, that
trials may not have satisfactory outcomes, the risk that the
ConFIrm and ConFIdence trials will not validate the potential
market for CB 4332; the risks that CB4332 and the Company’s
complement degraders have not yet started human clinical trials,
the risk Catalyst may elect to terminate or postpone ongoing
development programs, including development of MarzAA or any of the
Company’s complement assets; the risk that the Company will need to
raise additional capital, which may not be available on favorable
terms if at all; the risk that Biogen may terminate the Company's
agreement, and other risks described in the "Risk Factors" section
of the Company's Annual Report on Form 10-K filed with
the Securities and Exchange Commission (the “SEC”)
on March 4, 2021, the Quarterly Report on Form 10-Q filed with
the SEC on August 5, 2021 and in other filings filed from time to
time with the SEC. The Company does not assume any obligation
to update any forward-looking statements, except as required by
law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024